Myoclonic seizure therapy.
Article Tools
Add to My Bookmarks
Adds Article to your Entrepreneur Assist Bookmark page.
The FDA granted an additional indication for Keppra
(levetiracetam), manufactured by UCB (Brussels, Belgium), as an
adjunctive therapy in the treatment of myoclonic seizures in adults and
adolescents 12 years of age and older with juvenile myoclonic epilepsy.
Keppra is the first antiepileptic medication proven safe as an add-on
treatment for juvenile myoclonic epilepsy. The drug was previously
approved as an add-on therapy for the treatment of partial-onset
seizures in adults and children four years of age and older with
epilepsy.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: